<DOC>
	<DOCNO>NCT00895752</DOCNO>
	<brief_summary>The purpose study investigate effectiveness tolerability riluzole adult Fragile X Syndrome .</brief_summary>
	<brief_title>Riluzole Fragile X Syndrome</brief_title>
	<detailed_description>Fragile X Syndrome ( FXS ) represent common inherited form intellectual disability . FXS common male symptom associate disorder mark male . FXS associate characteristic physical feature , behavior , comorbidities . Those FXS often suffer behavioral difficulty include anxiety-related symptom ( shyness , social phobia , obsessive-compulsive disorder ( OCD ) symptom ) , attention deficit hyperactivity symptom ( overarousal , hyperactivity , distractibility , impulsivity ) aggressive/self-injurious behavior . Riluzole approve FDA use treat amyotrophic lateral sclerosis ( ALS ) adult . Recently , riluzole subject several open-label study describe use drug treatment-resistant depression OCD . Given overlap repetitive behavior FXS symptom OCD , logical study riluzole FXS give compound 's promise ameliorate treatment-refractory symptom OCD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Males female age 18 year old . Confirmed molecular diagnosis Fragile X Syndrome . Clinical Global Impression Severity ( CGIS ) score 3 great . Significant interfere repetitive behavior determine principal investigator . Must good health determine screen procedure include detailed medical history , complete physical neurological examination . Dosing concomitant medication study must remain stable . Pregnancy . Concomitant use another glutamatergic agent ( memantine , topiramate , amantadine , among others . Evidence prior trial riluzole and/or hypersensitivity/allergic reaction riluzole . Abnormal baseline liver function test screen history ; complete blood count abnormality screen history .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>